{
  "abstract": "Background: While PDZ-LIM domain-containing protein (PDLIM2) suppresses lung cancer, its clinical significance and therapeutic potential remain to be fully explored.\n\nMethods: Next-generation sequencing and immunohistochemistry of programmed death ligand 1 (PD-L1) were performed on lung adenocarcinoma (LUAD) tissues from 15,765 patients. PDLIM2 gene therapy was tested in syngeneic LUAD mouse models using intravenous nano-complexed plasmid DNA, alone or with chemoimmunotherapy.\n\nResults: PDLIM2-high tumors were more common in primary/local biopsies versus metastatic samples (73.1% vs 53.0%; p < 0.001). High PDLIM2 expression was linked to lower mutation rates in RB1, TP53, SMARCA4, STK11, and KEAP1, but increased EGFR mutations (all p < 0.01). PDLIM2-high tumors also showed increased immune cell infiltration, T cell-inflamed scores, and PD-L1 positivity (all p < 0.008). High PDLIM2 was associated with improved survival (24.1 vs 18.1 months; p < 0.001, HR = 0.84) and remained prognostic in multivariate analysis (HR = 0.88, 95% CI 0.83–0.93), as well as with longer pembrolizumab time, especially with platinum-based therapy (p = 0.012, HR = 0.867). In two LUAD mouse models, nanoPDLIM2 improved median overall survival versus chemoimmunotherapy alone (10–12.5 vs 8–9 days; N = 8; p = 0.0001, 0.0003).\n\nConclusion: PDLIM2 is a promising prognostic biomarker in LUAD linked to immune-receptive tumors. Preclinically, PDLIM2-based therapy enhances chemoimmunotherapy efficacy, though its predictive role warrants further evaluation.",
  "abstract_shown": true,
  "affiliations": [
    "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA USA",
    "UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA USA",
    "Caris Life Sciences, Phoenix, AZ USA",
    "Georgetown University, Washington, DC USA",
    "Penn State Cancer Institute, Penn State College of Medicine, Hershey, PA USA",
    "Montefiore Medical Center, Bronx, New York, NY USA",
    "Department of Immunology and Immune Therapeutics, Keck School of Medicine, University of Southern California, Los Angeles, CA USA",
    "Hastings Center for Pulmonary Research, Keck School of Medicine, University of Southern California, Los Angeles, CA USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Karam Ashouri",
      "orcid": "0009-0000-1825-1033"
    },
    {
      "affs": [
        1
      ],
      "name": "Fan Sun"
    },
    {
      "affs": [
        2
      ],
      "name": "Harris Krause"
    },
    {
      "affs": [
        2
      ],
      "name": "Andrew Elliott",
      "orcid": "0000-0001-8494-8031"
    },
    {
      "affs": [
        3
      ],
      "name": "Stephen V. Liu"
    },
    {
      "affs": [
        4
      ],
      "name": "Patrick C. Ma"
    },
    {
      "affs": [
        5
      ],
      "name": "Balazs Halmos",
      "orcid": "0000-0001-7548-8360"
    },
    {
      "affs": [
        0,
        6,
        7
      ],
      "name": "Gutian Xiao"
    },
    {
      "affs": [
        2
      ],
      "name": "Ari Vanderwalde"
    },
    {
      "affs": [
        0
      ],
      "name": "Jorge J. Nieva",
      "orcid": "0000-0003-1605-4719"
    },
    {
      "affs": [
        0,
        6,
        7
      ],
      "name": "Zhaoxia Qu",
      "orcid": "0000-0002-2769-9814"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/20srveh6x161e.bib",
  "cited_by": 1,
  "doi": "10.1038/s41416-026-03570-3",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13740284/",
  "id": "20srveh6x161e",
  "issns": [
    "0007-0920",
    "1532-1827"
  ],
  "landing_url": "https://doi.org/10.1038/s41416-026-03570-3",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Article"
    ],
    [
      "openalex",
      "2730|Lung Cancer Research Studies"
    ]
  ],
  "openalex": "W7201995531",
  "pdf_url": "https://www.nature.com/articles/s41416-026-03570-3.pdf",
  "pmcid": "PMC13740284",
  "pmid": "42570967",
  "published": "2026-08-08",
  "publisher": "Nature Publishing Group",
  "ris": "https://research.draconitic.com/paper/20srveh6x161e.ris",
  "sources": [
    {
      "first_seen": "2026-11-10T12:21:33Z",
      "native_id": "PMC13740284",
      "source": "pmc",
      "url": "https://doi.org/10.1038/s41416-026-03570-3"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Lung Cancer Research Studies",
      "subfield": "oncology"
    }
  ],
  "title": "Exploring PDLIM2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma",
  "title_text": "Exploring PDLIM2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma",
  "type": "peer-reviewed",
  "updated_at": "2026-11-10T12:21:33Z",
  "url": "https://research.draconitic.com/paper/20srveh6x161e",
  "venue": "British Journal of Cancer",
  "versions": []
}